Retatrutide vs tirzepatide — what the receptor differences mean

Tirzepatide gave us a glimpse of what happens when you stack incretin receptors instead of running them in isolation. Retatrutide takes the same architectural premise and adds a third lever — the glucagon receptor — that changes the metabolic profile in ways that are not just "more weight loss." The third receptor reaches into hepatic lipid handling, brown adipose tissue thermogenesis, and resting energy expenditure, and that combination produces a fundamentally different response curve than dual agonism does. If you are already comfortable with the GLP-1 basics, the practical question is no longer "does it work" but "what does each receptor contribute, and what should I monitor as a result."

This piece is a receptor-level breakdown. We will work through what each receptor does on its own, why GIP appears almost inert as monotherapy but becomes powerful in combination, what the glucagon component actually adds beyond the dual agonist baseline, and how the trial data lines up with the receptor pharmacology. Then we will close with the bloods you should run and when.

Receptor pharmacology primer

The three receptors involved are all class B G protein-coupled receptors, and all three signal predominantly through Gs to elevate intracellular cAMP. Same family, same primary signalling node. What makes the downstream effects so different is where each receptor is expressed.

GLP-1 receptors sit on pancreatic beta cells, where they amplify glucose-stimulated insulin release in a glucose-dependent fashion. They are also densely expressed in the area postrema and nucleus tractus solitarius — the brainstem regions that drive satiety and slow gastric emptying — and on alpha cells, where they suppress glucagon when glucose is normal or elevated. There is meaningful expression in the heart, kidney, and on parafollicular C-cells of the thyroid, which is why C-cell hyperplasia and medullary thyroid carcinoma flags appear on the prescribing label.

GIP receptors are found on pancreatic beta cells, where they also potentiate insulin secretion, but their expression in adipose tissue is the more interesting story. GIP signalling in white adipose tissue promotes lipid storage in the fed state and may sensitise adipocytes to insulin. There is increasing evidence of GIPR expression in skeletal muscle and in central feeding circuits, where GIP appears to exert a satiety effect that runs in parallel with — but mechanistically distinct from — GLP-1.

Glucagon receptors sit primarily on hepatocytes, where they drive gluconeogenesis and glycogenolysis. They are also expressed on brown adipose tissue, where activation increases UCP1-mediated thermogenesis, on the heart, where they have positive chronotropic effects, and at lower density in the kidney and adipose tissue.

GIP — the permissive co-agonist

GIP monotherapy is famously underwhelming for weight loss. Pure GIP receptor agonists tested in isolation produced minimal effects on body weight, and there is solid evidence that fasting GIP levels correlate positively with adiposity in untreated populations. So why does adding GIP agonism to GLP-1 agonism — as tirzepatide does — produce roughly double the weight loss of semaglutide at comparable doses?

Two complementary mechanisms appear to be operating. First, the insulinotropic synergy: GLP-1 and GIP both potentiate glucose-stimulated insulin secretion through cAMP, but they recruit subtly different intracellular pathways and act on overlapping but non-identical beta cell populations. Co-agonism produces an insulin response that is larger than the sum of the parts, and that improved post-prandial glucose handling reduces the metabolic cost of carbohydrate intake.

Second, GIP appears to act centrally on feeding circuits in a way that complements rather than duplicates GLP-1's satiety signal. There is also a tolerability story here — GIP signalling in the brainstem may dampen the nausea response to GLP-1 agonism, which is why high-dose tirzepatide is often better tolerated than equipotent doses of pure GLP-1 agonists. GIP is permissive in the sense that it makes GLP-1 work harder while making it easier to tolerate.

The glucagon component — what it adds

This is where retatrutide diverges. Adding glucagon receptor agonism to a GLP-1/GIP backbone is a deliberately counterintuitive move — glucagon is the classic counter-regulatory hormone that raises blood glucose. The reason it works in the context of triple agonism is that the GLP-1 component is suppressing hepatic glucose output and stimulating insulin secretion fast enough to swamp the glucagon-driven gluconeogenic signal. What you get instead is the catabolic and thermogenic side of glucagon physiology without a meaningful glucose excursion.

Three effects matter for body composition:

1. Brown adipose tissue activation. Glucagon receptor signalling on brown adipocytes upregulates UCP1 expression and uncouples mitochondrial respiration from ATP synthesis, increasing thermogenesis. This is a real, measurable contribution to total energy expenditure.

2. Increased resting energy expenditure. Across early-phase trials, retatrutide has been associated with a meaningful uptick in resting metabolic rate that does not appear with tirzepatide. The glucagon receptor is the most plausible mechanism.

3. Hepatic lipid mobilisation. Glucagon drives fatty acid oxidation in the liver and inhibits de novo lipogenesis. In a metabolic context where you are also restricting calories via GLP-1 mediated satiety, this accelerates clearance of intrahepatic triglyceride. The drop in liver fat seen in retatrutide trials is larger and faster than the drop seen with dual agonists at comparable weight loss percentages.

Fat loss vs muscle retention

The receptor profile predicts a different body composition trajectory. Glucagon receptor activation drives lipolysis in white adipose tissue more aggressively than GLP-1/GIP alone, which means a larger fraction of the weight lost should come from fat mass rather than lean mass. The DXA and MRI sub-studies from retatrutide trials are consistent with this — the ratio of fat-mass-lost to lean-mass-lost runs higher than what is reported for tirzepatide at similar total weight loss.

There is also emerging evidence that GIPR expression in skeletal muscle plays a muscle-protective role during a caloric deficit, possibly by enhancing insulin sensitivity and amino acid uptake at the myocyte level. Both compounds preserve muscle better than pure caloric restriction, but the combination of aggressive glucagon-driven fat oxidation plus GIP-mediated muscle preservation is what makes retatrutide's body composition shifts distinctive on paper.

Trial data — the numbers

Tirzepatide at the highest tested dose produced approximately 22.5% mean body weight reduction over 72 weeks in obese non-diabetic participants in the SURMOUNT-1 trial. Retatrutide at 12 mg weekly produced approximately 24.2% mean reduction over 48 weeks in its Phase 2 trial — a faster trajectory at a shorter duration. Importantly, the retatrutide weight loss curves had not plateaued at the trial endpoint, suggesting the eventual ceiling is higher.

Glycaemic effects were broadly comparable on a per-kilogram-lost basis, but retatrutide produced larger reductions in liver fat (assessed by MRI-PDFF) and a more pronounced drop in fasting triglycerides relative to weight loss. The metabolic biomarker profile is consistent with the glucagon receptor doing real work on hepatic lipid handling rather than just amplifying the GLP-1/GIP effect.

Metabolic marker trajectory

The order in which markers move tells you which receptors are dominant in the early weeks. Fasting glucose and post-prandial glucose drop within the first one to two weeks, driven by the GLP-1 component before meaningful weight loss has occurred. HbA1c follows over 8–12 weeks as the integrated glycaemic load comes down. Triglycerides typically drop in parallel with weight loss, but with retatrutide the drop tends to be steeper because hepatic VLDL secretion is being suppressed by glucagon-driven fatty acid oxidation. ALT and AST often dip below baseline within 12–16 weeks as hepatic lipid burden falls.

A useful framework: glycaemia moves first, body weight in the middle, and liver and lipid markers track the hepatic effect over months. With dual agonism, the glycaemic and weight effects dominate. With triple agonism, the hepatic and lipid signal is more prominent — and the time-to-effect on those markers is shorter.

Titration and tolerability

The glucagon component is not free. Adding glucagon receptor activation increases nausea, decreases appetite more aggressively, and adds a small but consistent uptick in resting heart rate that is not seen with dual agonism alone. This is why retatrutide trials use slower titration schedules than tirzepatide — typically 2 mg starting doses with monthly increments, rather than the faster ramp seen with dual agonists. Pushing the dose too quickly produces dose-limiting GI symptoms that often resolve completely with a slower escalation.

The cardiovascular profile is generally reassuring — the small heart rate elevation does not appear to translate into adverse outcomes — but it is worth noting in anyone with pre-existing tachyarrhythmia or autonomic dysfunction.

Practical monitoring protocol

Before starting either compound, run a baseline panel that captures the metabolic axes most likely to move. The minimum is fasting glucose, HbA1c, fasting insulin (for HOMA-IR calculation), full lipid panel including triglycerides and apoB if you can get it, ALT, AST, GGT, and a basic thyroid panel including TSH and ideally calcitonin if you have any thyroid history. For reference on what optimal ranges look like for each of these markers and how to read an Australian pathology report, see the complete guide to interpreting blood test results. A baseline DXA gives you a body composition reference point that mass alone cannot. For Australians who want to run this baseline panel without waiting for a GP referral, see our guide to private blood testing in Australia for the self-referral providers, marker availability, and indicative costs for each component.

At the 3-month checkpoint, repeat fasting glucose, HbA1c, the lipid panel, and liver enzymes. By this stage you should see HbA1c trending down, triglycerides dropping, and ALT/AST stable or improving. If liver enzymes are rising, that is a flag worth investigating before continuing — GLP-1 agonists themselves rarely cause hepatotoxicity, but rapid weight loss can transiently elevate enzymes through hepatic lipid flux.

At 6 months, repeat the full baseline panel including fasting insulin, and consider repeating the DXA. By this point the metabolic adaptation should be settling into a new steady state, and any unexpected drift in markers — particularly a rise in liver enzymes, a stalled HbA1c, or a triglyceride pattern that has not improved — warrants a pause and re-evaluation rather than dose escalation.

GLP-1 agonists also influence insulin sensitivity broadly, which has downstream effects on growth hormone pulsatility and IGF-1 dynamics. If you are tracking those markers separately, it is worth reading the IGF-1 and GH interpretation breakdown to understand what shifts are mechanistic versus what is noise. And because the GLP-1 receptor is expressed on thyroid C-cells, a baseline thyroid panel — including calcitonin in anyone with a family history of thyroid cancer or MEN2 — is the standard of care before initiating any GLP-1-based therapy, dual or triple.

The mechanistic short answer is that tirzepatide is an excellent dual agonist that produces strong weight and glycaemic outcomes, and retatrutide layers a hepatic and thermogenic axis on top of that — at the cost of a more demanding titration and a slightly broader monitoring footprint. The receptor differences are not abstract pharmacology; they map directly onto what changes in your bloodwork, in what order, and with what trade-offs.